| Autor: |
Vardi JR; Department of Obstetrics and Gynecology, Maimonides Medical Center, State University of New York, Brooklyn 11219., Rafla SD, Malhotra C, Tadros G, Charney T, Shebes M, Berkowitz BJ, Kehoe JE, Tancer LM |
| Jazyk: |
angličtina |
| Zdroj: |
Gynecologic oncology [Gynecol Oncol] 1989 Jul; Vol. 34 (1), pp. 12-5. |
| DOI: |
10.1016/0090-8258(89)90096-6 |
| Abstrakt: |
The purpose of this study is to evaluate the feasibility of early use of modified PAC-1 chemotherapy following debulking surgery and its efficacy by assessing disease status during a second-look operation. Twenty-six consecutive previously untreated patients with stage III ovarian carcinoma were evaluated in a prospective study over the 5-year period March 1981 to August 1986. Initial exploratory laparotomy was performed for staging and maximum cytoreduction. Within 24 hr postoperative modified PAC-1 (M-PAC-1) combination chemotherapy was administered and then repeated every 4 weeks for 11 months which was then followed by second-look operation. Patients were analyzed according to the following pretreatment characteristics: age, FIGO stage, histologic tumor type, extent of initial surgery, size of residual tumor, and findings during second-look. Nineteen patients were evaluable. No evidence of either microscopic or macroscopic disease was noted in 15 patients (79%), whereas the remaining 4 (21%) exhibited persistent disease. Of the remaining 7 patients not undergoing SLO, 4 completed 12 courses of chemotherapy but did not undergo surgery for medical reason (n = 2) or patient refusal (n = 2). Two more patients refused chemotherapy after 9 courses and the seventh patient expired with persistent disease after 8 courses. The early use of combination chemotherapy was well tolerated. Neurological, hematological, and renal toxicity was never severe enough to cause discontinuation of therapy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
